CLDN18 and neoplasm: In the NCT01630083 study, which included 161 advanced/recurrent gastric and GEJ cancer patients with CLDN18.2 expression ≥2+ in ≥40% of tumor cells who were not eligible for trastuzumab therapy, patients were randomized 1:1 to receive first-line EOX (epirubicin 50 mg/m2 and oxaliplatin 130 mg/m2 d1, and capecitabine 625 mg/m2 bid, d1–21; qd22) with or without zolbetuximab (loading dose 800 mg/m2, then 600 mg/m2 d1, qd21).